

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**202107Orig1s000**

**MEDICAL REVIEW(S)**

## CLINICAL REVIEW

Application Type NDA  
Application Number(s) 202107  
Priority or Standard Standard

Submit Date(s)  
Received Date(s) April 18, 2011  
PDUFA Goal Date February 18, 2012  
Division / Office DMEP

Reviewer Name(s) Zemskova Marina, MD  
Review Completion Date January 13, 2012

Established Name Mifepristone  
(Proposed) Trade Name Korlym  
Therapeutic Class  
Applicant Corcept Therapeutics

Formulation(s) Oral tablets  
Dosing Regimen 300-1200 mg once a day  
Indication(s) Endogenous Cushing's  
syndrome  
Intended Population(s) Adults

Template Version: [March 6, 2009](#)

## Table of Contents

|          |  |           |
|----------|--|-----------|
| <b>1</b> | <b>RECOMMENDATIONS/RISK BENEFIT ASSESSMENT.....</b>                                    | <b>9</b>  |
| 1.1      | Recommendation on Regulatory Action .....  | 9         |
| 1.2      | Risk Benefit Assessment .....  | 9         |
| 1.3      | Recommendations for Postmarket Risk Evaluation and Mitigation Strategies.....          | 14        |
| 1.4      | Recommendations for Postmarket Requirements and Commitments .....                      | 15        |
| <b>2</b> | <b>INTRODUCTION AND REGULATORY BACKGROUND.....</b>                                     | <b>15</b> |
| 2.1      | Product Information.....   | 15        |
| 2.2      | Tables of Currently Available Treatments for Proposed Indications .....                | 16        |
| 2.3      | Availability of Proposed Active Ingredient in the United States .....                  | 18        |
| 2.4      | Important Safety Issues With Consideration to Related Drugs.....                       | 18        |
| 2.5      | Summary of Presubmission Regulatory Activity Related to Submission .....               | 19        |
| 2.6      | Other Relevant Background Information .....  | 22        |
| <b>3</b> | <b>ETHICS AND GOOD CLINICAL PRACTICES .....</b>  | <b>22</b> |
| 3.1      | Submission Quality and Integrity.....  | 22        |
| 3.2      | Compliance with Good Clinical Practices.....   | 22        |
| 3.3      | Financial Disclosures.....   | 24        |
| <b>4</b> | <b>SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW<br/>DISCIPLINES.....</b> | <b>24</b> |
| 4.1      | Chemistry Manufacturing and Controls .....   | 24        |
| 4.2      | Clinical Microbiology.....   | 25        |
| 4.3      | Preclinical Pharmacology/Toxicology .....  | 25        |
| 4.4      | Clinical Pharmacology .....  | 26        |
| 4.4.1    | Mechanism of Action .....  | 26        |
| 4.4.2    | Pharmacodynamics.....  | 27        |
| 4.4.3    | Pharmacokinetics.....  | 27        |
| <b>5</b> | <b>SOURCES OF CLINICAL DATA.....</b>   | <b>31</b> |
| 5.1      | Tables of Studies/Clinical Trials .....  | 31        |
| 5.2      | Review Strategy.....   | 35        |
| 5.3      | Discussion of Individual Studies/Clinical Trials .....                                 | 35        |
| 5.3.1    | Study C1073-400 (Study 400).....   | 35        |
| 5.3.2    | Study C1073-415 (Study 415).....   | 48        |
| 5.3.3    | Non-Cushing’s Corcept-sponsored studies.....   | 52        |
| <b>6</b> | <b>REVIEW OF EFFICACY .....</b>  | <b>62</b> |
|          | Efficacy Summary .....   | 62        |
| 6.1      | Indication.....  | 62        |
| 6.1.1    | Methods.....   | 62        |
| 6.1.2    | Demographics.....  | 62        |

|          |  |            |
|----------|--|------------|
| 6.1.3    | Subject Disposition.....   | 70         |
| 6.1.4    | Analysis of Primary Endpoint(s).....   | 72         |
| 6.1.5    | Analysis of Secondary Endpoints(s) .....   | 83         |
| 6.1.6    | Other Endpoints.....   | 90         |
| 6.1.7    | Subpopulations .....   | 96         |
| 6.1.8    | Analysis of Clinical Information Relevant to Dosing Recommendations .....                    | 97         |
| 6.1.9    | Discussion of Persistence of Efficacy and/or Tolerance Effects.....                          | 98         |
| 6.1.10   | Additional Efficacy Issues/Analyses.....   | 98         |
| <b>7</b> | <b>REVIEW OF SAFETY .....</b>  | <b>102</b> |
|          | Safety Summary.....  | 102        |
| 7.1      | Methods .....  | 102        |
| 7.1.1    | Studies/Clinical Trials Used to Evaluate Safety.....   | 103        |
| 7.1.2    | Categorization of Adverse Events.....  | 103        |
| 7.1.3    | Pooling of Data across Studies/Clinical Trials to Estimate and Compare Incidence .....       | 103        |
| 7.2      | Adequacy of Safety Assessments.....  | 103        |
| 7.2.1    | Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations ..... | 104        |
| 7.2.2    | Explorations for Dose Response .....   | 107        |
| 7.2.3    | Special Animal and/or In Vitro Testing .....   | 109        |
| 7.2.4    | Routine Clinical Testing.....  | 110        |
| 7.2.5    | Metabolic, Clearance, and Interaction Workup.....  | 110        |
| 7.2.6    | Evaluation for Potential Adverse Events for Similar Drugs in Drug Class .....                | 110        |
| 7.3      | Major Safety Results .....   | 110        |
| 7.3.1    | Deaths.....  | 110        |
| 7.3.2    | Nonfatal Serious Adverse Events.....   | 113        |
| 7.3.3    | Dropouts and/or Discontinuations.....  | 122        |
| 7.3.4    | Significant Adverse Events .....   | 126        |
| 7.3.5    | Submission Specific Primary Safety Concerns.....   | 126        |
| 7.4      | Supportive Safety Results.....   | 151        |
| 7.4.1    | Common Adverse Events.....   | 151        |
| 7.4.2    | Laboratory Findings .....  | 156        |
| 7.4.3    | Vital Signs .....  | 167        |
| 7.4.4    | Electrocardiograms (ECGs) .....  | 168        |
| 7.4.5    | Special Safety Studies/Clinical Trials .....   | 169        |
| 7.4.6    | Immunogenicity.....  | 175        |
| 7.5      | Other Safety Explorations .....  | 175        |
| 7.5.1    | Dose Dependency for Adverse Events.....  | 175        |
| 7.5.2    | Time Dependency for Adverse Events.....  | 175        |
| 7.5.3    | Drug-Demographic Interactions.....   | 177        |
| 7.5.4    | Drug-Disease Interactions .....  | 177        |
| 7.5.5    | Drug-Drug Interactions .....   | 178        |
| 7.6      | Additional Safety Evaluations.....   | 180        |

|          |  |            |
|----------|--|------------|
| 7.6.1    | Human Carcinogenicity.....                                   | 180        |
| 7.6.2    | Human Reproduction and Pregnancy Data .....                  | 180        |
| 7.6.3    | Pediatrics and Assessment of Effects on Growth.....          | 181        |
| 7.6.4    | Overdose, Drug Abuse Potential, Withdrawal and Rebound ..... | 182        |
| 7.7      | Additional Submissions / Safety Issues.....                  | 182        |
| 7.7.1    | 120-day safety update.....                                   | 182        |
| 7.7.2    | Literature review.....                                       | 186        |
| <b>8</b> | <b>POSTMARKET EXPERIENCE.....</b>                            | <b>189</b> |
| <b>9</b> | <b>APPENDICES.....</b>                                       | <b>190</b> |
| 9.1      | Literature Review/Reference.....                             | 190        |
| 9.1.1    | Literature Review.....                                       | 190        |
| 9.1.2    | References.....  | 197        |
| 9.2      | Labeling Recommendations .....                               | 200        |
| 9.3      | Advisory Committee Meeting.....                              | 200        |

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.